Larimar Therapeutics announced plans to initiate a rolling Biologics License Application (BLA) submission in June 2026 for nomlabofusp, targeting accelerated FDA approval for treating Friedreich’s ataxia. The company expects to submit nonclinical and clinical data modules first, with the final chemistry, manufacturing, and controls (CMC) module to follow in the second half of 2026. Topline data from an open-label study supporting the BLA is anticipated in Q2 2026, alongside plans to start a global Phase 3 confirmatory trial mid-year. Larimar holds $200.4 million in cash, supporting operations into Q2 2027, and aims for a potential product launch in the first half of 2027 if approved.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Frasers Group PLC has withheld financial guidance for the upcoming year due to uncertainty around its takeover bids for Hugo Boss and Accent Group. The retailer's full-year adjusted profit before tax fell 4% to £538 million, impacted by asset impairm...
Ethereum rose 3.17% to $1,923.53, outperforming Bitcoin's modest 0.18% gain to $64,588.87, signaling an early rotation toward large-cap altcoins. Despite this, overall market activity slowed, with declines in DeFi, stablecoin, and derivatives trading...
Gabriel Holding A/S has agreed to sell its European FurnMaster furniture manufacturing operations, including subsidiaries in Poland and Lithuania, to Leggett & Platt for an initial price of approximately EUR 9 million, with a possible additional paym...
A Gaza resident raised over £55,000 on GoFundMe to support his family but faced issues as the platform cannot pay directly to Gaza, forcing funds through intermediaries who failed to deliver the full amount. This highlights a broader problem in human...
